Company / SG&A Expense
Bio-Rad Laboratories SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$844.3M
FY2025
5-year range
$814.0M / $877.1M
FY2021-FY2025
Trend
+3.7%
vs FY2024
Sector context
#51 of 158
Health Care
What the data says
At $844M, Bio-Rad Laboratories's sg&a expense ranks #108 of 158 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $762M in FY2017 to $877M in FY2021.
Based on SEC 10-K filings.
$844M in FY2025 with a 5-year CAGR of +0.2%.
Remained stable around $844M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +0.7%
- 5-Year CAGR
- +0.2%
- 10-Year CAGR
- -
Sector benchmark
#108 of 158 in Health CareTop 68% of 158This company $844.3M Sector average $175.9B
▼
-99.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 3.7% year-over-year.
- Ranks #51 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2021.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $844.3M | +3.7% |
| FY2024 | $814.0M | -3.3% |
| FY2023 | $841.7M | +1.7% |
| FY2022 | $827.8M | -5.6% |
| FY2021 | $877.1M | +5.1% |
| FY2020 | $834.8M | +1.2% |
| FY2019 | $824.6M | +1.2% |
| FY2018 | $814.7M | +6.9% |
| FY2017 | $762.0M | -5.7% |
| FY2016 | $808.2M | +6.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026